Senhwa Biosciences Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Senhwa Biosciences.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth	51.0%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

Analysts Are Optimistic We'll See A Profit From Senhwa Biosciences, Inc. (GTSM:6492)

Mar 18

Recent updates

Analysts Are Optimistic We'll See A Profit From Senhwa Biosciences, Inc. (GTSM:6492)

Mar 18

Does This Valuation Of Senhwa Biosciences, Inc. (GTSM:6492) Imply Investors Are Overpaying?

Jan 19

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Senhwa Biosciences has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

TPEX:6492 - Analysts future estimates and past financials data (TWD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
9/30/2024	1	-297	-286	-284	N/A
6/30/2024	1	-292	-282	-280	N/A
3/31/2024	1	-286	-275	-273	N/A
12/31/2023	1	-296	-291	-286	N/A
9/30/2023	1	-305	-332	-327	N/A
6/30/2023	1	-312	-333	-328	N/A
3/31/2023	1	-345	-381	-376	N/A
12/31/2022	1	-350	-400	-400	N/A
9/30/2022	1	-340	-375	-374	N/A
6/30/2022	1	-345	-374	-374	N/A
3/31/2022	1	-316	-337	-337	N/A
12/31/2021	1	-329	-300	-300	N/A
9/30/2021	1	-328	-329	-329	N/A
6/30/2021	1	-358	-287	-286	N/A
3/31/2021	1	-362	-291	-290	N/A
12/31/2020	1	-355	-273	-273	N/A
9/30/2020	1	-352	-249	-249	N/A
6/30/2020	0	-316	-294	-294	N/A
3/31/2020	0	-339	-303	-303	N/A
12/31/2019	0	-391	-385	-385	N/A
9/30/2019	0	-410	-393	-393	N/A
6/30/2019	1	-416	-397	-396	N/A
3/31/2019	1	-451	-416	-415	N/A
12/31/2018	1	-376	-375	-374	N/A
9/30/2018	1	-394	-348	-347	N/A
6/30/2018	0	-416	N/A	-381	N/A
3/31/2018	0	-354	N/A	-346	N/A
12/31/2017	N/A	-372	N/A	-326	N/A
9/30/2017	N/A	-333	N/A	-314	N/A
6/30/2017	0	-283	N/A	-255	N/A
3/31/2017	0	-286	N/A	-250	N/A
12/31/2016	0	-255	N/A	-221	N/A
9/30/2016	0	-233	N/A	-216	N/A
6/30/2016	N/A	-212	N/A	-198	N/A
3/31/2016	N/A	-194	N/A	-179	N/A
12/31/2015	N/A	-194	N/A	-174	N/A
9/30/2015	2	-180	N/A	-171	N/A
6/30/2015	5	-182	N/A	-173	N/A
3/31/2015	14	-165	N/A	-157	N/A
12/31/2014	24	-157	N/A	-141	N/A
9/30/2014	31	-139	N/A	-124	N/A
6/30/2014	39	-120	N/A	-106	N/A
3/31/2014	32	-117	N/A	-101	N/A
12/31/2013	26	-113	N/A	-96	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 6492's forecast earnings growth is above the savings rate (1.1%).

Earnings vs Market: Insufficient data to determine if 6492's earnings are forecast to grow faster than the TW market

High Growth Earnings: Insufficient data to determine if 6492's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if 6492's revenue is forecast to grow faster than the TW market.

High Growth Revenue: Insufficient data to determine if 6492's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 6492's Return on Equity is forecast to be high in 3 years time

Senhwa Biosciences Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

No longer forecast to breakeven

Price target decreased to NT$143

Forecast breakeven date pushed back to 2022

Analysts Are Optimistic We'll See A Profit From Senhwa Biosciences, Inc. (GTSM:6492)

Recent updates

Third quarter 2024 earnings released: NT$0.91 loss per share (vs NT$0.84 loss in 3Q 2023)

Senhwa Biosciences Announces First Patient Dosed in the Phase I/Ii Study of Silmitasertib in Children and Young Adults with Relapsed Refractory Solid Tumors

Senhwa Biosciences, Inc. Announces US FDA Issues Study May Proceed Letter for the Pilot Study of Pidnarulex Pharmacodynamics in Patients with Advanced Solid Tumors, Sponsored by the Us National Cancer Institute

Senhwa Biosciences, Inc. Announces IND Submission to US FDA for Pilot Study of Pidnarulex Pharmacodynamics in Patients with Advanced Solid Tumors Sponsored by NCI

US FDA Grants RPD Designation to Senhwa Biosciences Silmitasertib for Pediatric Neuroblastoma

Senhwa Biosciences, Inc. Announces Phase Ib Expansion Study Abstract of Cx-5461 in Solid Tumours and Brca2 And/Or Palb2 Mutations

Senhwa Biosciences, Inc. Announces Promotion of Sarah Chang as Executive Vice President, Effective August 9, 2024

Senhwa Biosciences, Inc. Receives US FDA Study May Proceed Letter for the Phase I/II Study of Silmitasertib (CX-4945) in Combination with Chemotherapy in Children and Young Adults with Relapsed Refractory Solid Tumors

Senhwa Biosciences, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Senhwa Biosciences Announces IND Submission to US FDA for the Phase I/II Study of Silmitasertib in Children /Dearyoung Adults with Relapsed Refractory Solid Tumors

First quarter 2024 earnings released: NT$0.71 loss per share (vs NT$0.82 loss in 1Q 2023)

Senhwa Biosciences, Inc. to Report Q1, 2024 Results on May 13, 2024

Senhwa Biosciences, Inc., Annual General Meeting, Jun 21, 2024

Senhwa Biosciences Announces First Patient Dosed in the Phase II Study of Silmitasertib in Patients with Community-Acquired Pneumonia Associated with Viral Infection in Taiwan

Full year 2023 earnings released: NT$3.32 loss per share (vs NT$3.92 loss in FY 2022)

Senhwa Biosciences, Inc. Decides to Early Terminate the Phase II study of Silmitasertib to treat hospitalized patients with COVID-19

Senhwa Biosciences Receives Taiwan FDA IND Approval for Phase Ii Study of Silmitasertib in Patients with Community-Acquired Pneumonia (Cap) Associated with Viral Infection

Third quarter 2023 earnings released: NT$0.84 loss per share (vs NT$0.93 loss in 3Q 2022)

Senhwa Biosciences, Inc. Announces First Patient Successfully Dosed in Taiwan Phase II Study of Silmitasertib in Hospitalized Adults with COVID-19

New minor risk - Share price stability

Senhwa Biosciences Announces Investigational New Drug Submission to U.S. Food and Drug Administration for Phase II Study of Silmitasertib in Patients with Community-Acquired Pneumonia Associated with Viral Infection

First half 2023 earnings released: NT$1.54 loss per share (vs NT$1.96 loss in 1H 2022)

Less than half of directors are independent

Third quarter 2022 earnings released: NT$0.93 loss per share (vs NT$0.97 loss in 3Q 2021)

Third quarter 2022 earnings released: NT$0.93 loss per share (vs NT$0.97 loss in 3Q 2021)

Senhwa Biosciences, Inc. Announces First Patient Successfully Dosed in Phase I Study of Pindnarulex in Combination with Pfizer's Talazoparib for the Treatment of Prostate Cancer

First half 2022 earnings released: NT$1.96 loss per share (vs NT$1.78 loss in 1H 2021)

Senhwa Biosciences, Inc. Pindnarulex in Combination Study with Pfizer's Talazoparib for the Treatment of Prostate Cancer Granted Approval to Initiate from Australian HREC

No longer forecast to breakeven

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to NT$143

Less than half of directors are independent

Senhwa Biosciences, Inc. Presents Positive Initial Data from Phase 1 Clinical Trial of Silmitasertib Used to Treat Patients with Advanced Basal Cell Carcinoma at 2022 AAD Annual Meeting

Forecast breakeven date pushed back to 2022

Less than half of directors are independent

Full year 2021 earnings: EPS and revenues miss analyst expectations

Senhwa Biosciences, Inc. Receives US FDA Fast Track Designation for the Treatment of Solid Tumors with BRCA1/2, PALB2 and Other HR Gene Mutations

Us Food and Drug Administration Grants Orphan Drug Designation to Senhwa Biosciences, Inc. for Silmitasertib, A Highly Selective Inhibitor of Casein Kinase 2 (Ck2)

Third quarter 2021 earnings released: NT$0.97 loss per share (vs NT$1.53 loss in 3Q 2020)

Senhwa Announces Acceptance of Early Positive COVID-19 Phase II Study Abstract for Presentation at the ISIRV-WHO Conference

Senhwa Biosciences, Inc. Announces First Patient Successfully Dosed in Phase 1B Expansion Study of Pidnarulex to Treat Solid Tumors with Specific Homologous Recombination Gene Mutations

Senhwa Biosciences Announces Dose Escalation Initiation of the Phase I Trial of Pidnarulex as a Treatment for Advanced Hematological Malignancies

Senhwa's Silmitasertib Receives US FDA Fast Track Designation for the Treatment of Recurrent Sonic Hedgehog Driven Medulloblastoma

Senhwa Announces Ind Submission to India's Cdsco of A Phase II Clinical Study for Silmitasertib as A Potential Covid-19 Treatment

First quarter 2021 earnings released: NT$1.02 loss per share (vs NT$1.13 loss in 1Q 2020)

Full year 2020 earnings released: NT$4.49 loss per share (vs NT$5.26 loss in FY 2019)

Analysts Are Optimistic We'll See A Profit From Senhwa Biosciences, Inc. (GTSM:6492)

New 90-day low: NT$162

Does This Valuation Of Senhwa Biosciences, Inc. (GTSM:6492) Imply Investors Are Overpaying?

New 90-day low: NT$172

Senhwa Biosciences Presents Positive Cholangiocarcinoma Data

Senhwa Announces the First Patient Enrolled in an Investigator Initiated Trial Of Silmitasertib as a Treatment for COVID-19

Senhwa Announces Multiple IND Application Submissions to US FDA and Health Canada for the Treatment of Solid Tumors with BRCA2 or PALB2 Mutations

Earnings beat expectations

Third quarter 2020 earnings released: NT$1.52 loss per share

CARE GA Receives Study May Proceed Letter from US FDA to Initiate Phase II Clinical Trial of Senhwa's Silmitasertib in COVID-19 Patients

Senhwa Announces Multiple INDApplication Submissions to U.S. FDA for Silmitasertib as A Potential Treatment for COVID-19

New 90-day high - NT$181

First half earnings released

New 90-day high - NT$180

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies